Tipifarnib in Treating Patients With Recurrent Bladder Cancer
- Conditions
- Bladder Cancer
- Registration Number
- NCT00047216
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent bladder cancer.
- Detailed Description
OBJECTIVES:
* Determine the 1-year recurrence-free survival rate of patients with stage 0 or I recurrent transitional cell carcinoma of the bladder treated with tipifarnib.
OUTLINE: This is a multicenter study.
Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 37 patients will be accrued for this study within 18 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-year recurrence-free survival
- Secondary Outcome Measures
Name Time Method Molecular changes in the host tissue Progression rate at 3, 6, 9, and 12 months Recurrence rate at 3, 6, 9, and 12 months Time to treatment failure Survival rate
Trial Locations
- Locations (7)
Louis A. Weiss Memorial Hospital
🇺🇸Chicago, Illinois, United States
University of Chicago Cancer Research Center
🇺🇸Chicago, Illinois, United States
St. Joseph's Hospital
🇨🇦Hamilton, Ontario, Canada
Vancouver General Hospital
🇨🇦Vancouver, British Columbia, Canada
London Regional Cancer Program at London Health Sciences Centre
🇨🇦London, Ontario, Canada
Sunnybrook and Women's College Health Sciences Centre
🇨🇦North York, Ontario, Canada
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada